

NeXstar Pharmaceuticals Incorporated

[View the current NeXstar Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7521-NeXstar+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/7521-NeXstar+Pharmaceuticals+Incorporated.html>)

Contact Details:

2860 Wilderness Place

Boulder

CO

80301

United States of America

Tel: 303 444 5893

Fax: 303 444 0672

Email:

NeXstar Pharmaceuticals, Inc., is an integrated biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious oncological, hematological and infectious diseases. NeXstar Pharmaceuticals employs a broad range of proprietary technologies in the discovery and formulation of pharmaceutical products, including the Company's liposome drug delivery technology; a powerful combinatorial chemistry technology known as the SELEX process that rapidly identifies novel oligonucleotide compounds with potential therapeutic and diagnostic benefits; and Evolutionary Chemistry, designed to rapidly discover small organic molecules to serve as orally available drugs. The Company's technologies have produced two approved drugs and several drug candidates that are in clinical or preclinical development and have provided the basis for a significant pipeline of drug development candidates.

Recent Publications by NeXstar Pharmaceuticals Incorporated:



- [Theoretical principles of in vitro selection using combinatorial nucleic acid libraries.](#)
*A new paradigm for drug discovery and biological research has developed...*9th May, 2008
NeXstar Pharmaceuticals, Boulder, Colorado, USA.- *Curr Protoc Nucleic Acid Chem.* 2000 Feb;Chapter 9:Unit 9.1. ([DOI Direct Link](#))
- [Tumor targeting by an aptamer.](#)
*Aptamers are small oligonucleotides that are selected to bind tightly and...*20th June, 2006
NeXstar Pharmaceuticals,- *J Nucl Med.* 2006 Apr;47(4):668-78.
- [Aptamers as reagents for high-throughput screening.](#)
*The identification of new drug candidates from chemical libraries is a...*5th January, 2002
NeXstar Pharmaceuticals/Gilead Sciences, Boulder, CO, USA.- *Biotechniques.* 2001 May;30(5):1094-6, 1098, 1100 passim.

- [Diels--Alder bioconjugation of diene-modified oligonucleotides.](#)
*In an effort to offer complementary technology for covalent biomolecule...*14th September, 2001
NeXstar Pharmaceuticals, 2860 Wilderness Place, Boulder, Colorado 80301,- J Org Chem. 2001 Aug 10;66(16):5352-8.
- [Selection for RNA: peptide recognition through sulfur alkylation chemistry.](#)
*While T cells have been clearly implicated in a number of disease...*28th February, 2001
NeXstar Pharmaceuticals, Boulder, Colorado 80301, USA.- Methods Enzymol. 2000;318:229-37.
- [Identification of T cell ligands in a library of peptides covalently attached to HLA-DR4.](#)
*While T cells have been clearly implicated in a number of disease...*19th September, 2000
Nexstar Pharmaceuticals, Boulder, CO 80301, USA.- J Immunol. 2000 Aug 15;165(4):2040-7.
- [Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration.](#)
*Amikacin in small, low-clearance liposomes (MiKasome) has prolonged plasma...*2nd September, 2000
Biopharmaceutics Group, NeXstar Pharmaceuticals, Inc., Boulder, CO 80301,- J Drug Target. 1999;6(6):415-26. ([DOI Direct Link](#))
- [Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo.](#)
*Therapeutic and diagnostic applications have been envisioned for aptamers,...*12th August, 2000
NeXstar Pharmaceuticals, Inc., Boulder, CO 80301, USA.- Antisense Nucleic Acid Drug Dev. 2000 Apr;10(2):63-75.
- [Ligand-targeted liposomes.](#)
*Liposomes have gained increased attention as systemic drug delivery...*6th June, 2000
NeXstar Pharmaceuticals, Inc., Boulder, CO, USA- Adv Drug Deliv Rev. 1998 Feb 2;29(3):249-271.
- [The use of aptamers in large arrays for molecular diagnostics.](#)
*BACKGROUND: Aptamers are single-stranded oligonucleotides derived from an...*25th March, 2000
NeXstar Pharmaceuticals, Inc, Boulder, Colorado 80301, USA.- Mol Diagn. 1999 Dec;4(4):381-8. ([DOI Direct Link](#))
- [Signal amplification through nucleotide extension and excision on a dendritic DNA platform.](#)
*Techniques that provide strong signal amplification are useful in...*10th March, 2000
NeXstar Pharmaceuticals Inc., 2860 Wilderness Place, Boulder, CO 80301,- Nucleic Acids Res. 2000 Apr 1;28(7):E21.
- [Polymerization of 2'-fluoro- and 2'-O-methyl-dNTPs by human DNA polymerase alpha, polymerase gamma, and primase.](#)
*Studies were undertaken to assess the ability of human polymerase alpha...*8th March, 2000
NeXstar Pharmaceuticals, Inc., Boulder, CO 80301, USA.- Biochem Pharmacol. 2000 May 1;59(9):1045-52.
- [An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks \(Marmota monax\).](#)
*The toxicities of 2'-fluorouridine (2'-FU) and 2'-fluorocytidine-HCl...*10th December, 1999
NeXstar Pharmaceuticals, Inc., Boulder, Colorado 80301, USA.- Toxicol Pathol. 1999 Nov-Dec;27(6):607-17.
- [Estimation of SELEX pool size by measurement of DNA renaturation rates.](#)
*We report a general method of measuring the complexity of SELEX pools. In...*26th November, 1999
NeXstar Pharmaceuticals, Inc., Boulder, Colorado 80301, USA.- RNA. 1999 Oct;5(10):1326-32.
- [Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro.](#)
*VEGF (vascular endothelial growth factor) overproduction has been...*5th November, 1999
Cell Biology/Life Sciences, NeXstar Pharmaceuticals, Inc., Boulder,- In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):533-42. ([DOI Direct Link](#))

Press Releases on NeXstar Pharmaceuticals Incorporated:

Somaxons Silenor approved in US	19th March, 2010	<i>The US FDA has approved Somaxon Pharmaceuticals' insomnia drug Silenor (low-dose doxepin) after a long approval process</i>
Somaxon Announces FDA Approval Of Silenor(R) (doxepin) For The Treatment Of Insomnia	19th March, 2010	<i>Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of</i>
Single dose Pharmacokinetics of Famciclovir in Infants and Population Pharmacokinetic Analysis in Infants and Children [Article]	19th March, 2010	<i>Single-dose Pharmacokinetics of Famciclovir in Infants and Population Pharmacokinetic Analysis in Infants and Children Jeffrey Blumer, Adib Rodriguez, Pablo J. Snchez, William Sallas, Guenther Kaiser,</i>
Alpharma to Pay \$42.5 Million in False Claims Settlement	19th March, 2010	<i>Drugmakers Alpharma and Alpharma Pharmaceuticals have agreed to pay \$42</i>
FDA Requests REMS, Final Label for Once Weekly Diabetes Drug	19th March, 2010	<i>The FDA has asked Eli Lilly and Amylin Pharmaceuticals for final labeling information and a risk evaluation and mitigation strategy (REMS) before it decides</i>

BioNews Results for NeXstar Pharmaceuticals Incorporated



- [BUYINS.NET: SLXP, NCS, ONTY, YORW, CALP, NXST Expected To Be Lowe...](#)
Zibb: Mar 8 2010 10:31AM Matching: nexstar pharmaceuticals
- [BUYINS.NET: SLXP, NCS, ONTY, YORW, CALP, NXST Expected To Be Lower After Earnings Releases on Tuesday](#)
RBC Dain Rauscher: Mar 8 2010 10:19AM Matching: nexstar pharmaceuticals
- [BUYINS.NET: SLXP, NCS, ONTY, YORW, CALP, NXST Expected To Be Lower After Earnings Releases on Tuesday](#)
TradingMarkets: Mar 8 2010 9:35AM Matching: nexstar pharmaceuticals

NeXstar Pharmaceuticals Incorporated Clinical Trials:



- [A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine \(ABV\) in the Treatment of HIV-Associated Kaposi's Sarcoma.](#)

NeXstar Pharmaceuticals Incorporated Patents:



- 5846713- [High affinity HKGF nucleic acid ligands and inhibitors](#)
- 5945527- [Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide](#)
- 5958449- [Antibiotic formulation and use for bacterial infections](#)
- 5958691- [High affinity nucleic acid ligands containing modified nucleotides](#)
- 5959100- [Pyrimidine nucleosides as therapeutic and diagnostic agents](#)
- 5962219- [Systematic evolution of ligands by exponential enrichment: chemi-selex](#)
- 5965156- [Amphotericin B liposome preparation](#)
- 5972599- [High affinity nucleic acid ligands of cytokines](#)
- 5989823- [Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction](#)
- 5998142- [Systematic evolution of ligands by exponential enrichment: chemi-SELEX](#)
- 6001577- [Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex](#)
- 5888537- [Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties](#)
- 5874557- [Nucleic acid ligand inhibitors to DNA polymerases](#)
- 5874532- [Method for solution phase synthesis of oligonucleotides and peptides](#)
- 5849479- [High-affinity oligonucleotide ligands to vascular endothelial growth factor \(VEGF\)](#)
- 5849890- [High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones](#)
- 5853984- [Use of nucleic acid ligands in flow cytometry](#)
- 5859228- [Vascular endothelial growth factor \(VEGF\) nucleic acid ligand complexes](#)
- 5861254- [Flow cell SELEX](#)
- 5864026- [Systematic evolution of ligands by exponential enrichment: tissue selex](#)
- 5869641- [High affinity nucleic acid ligands of CD4](#)
- 5871924- [Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis](#)
- 5874104- [Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics](#)
- 5874218- [Method for detecting a target compound in a substance using a nucleic acid ligand](#)
- 6001988- [High affinity nucleic acid ligands to lectins](#)
- 6011020- [Nucleic acid ligand complexes](#)
- 6140490- [High affinity nucleic acid ligands of complement system proteins](#)
- 6143882- [Urea nucleosides as therapeutic and diagnostic agents](#)

- 6147204- [Nucleic acid ligand complexes](#)
- 6168778- [Vascular endothelial growth factor \(VEGF\) Nucleic Acid Ligand Complexes](#)
- 6171795- [Nucleic acid ligands to CD40ligand](#)
- 6177555- [Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction](#)
- 6177557- [High affinity ligands of basic fibroblast growth factor and thrombin](#)
- 6183967- [Nucleic acid ligand inhibitors to DNA polymerases](#)
- 6184364- [High affinity nucleic acid ligands containing modified nucleotides](#)
- 6207816- [High affinity oligonucleotide ligands to growth factors](#)
- 6127119- [Nucleic acid ligands of tissue target](#)
- 6124449- [High affinity TGF.beta. nucleic acid ligands and inhibitors](#)
- 6120800- [Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties](#)
- 6013443- [Systematic evolution of ligands by exponential enrichment: tissue SELEX](#)
- 6020130- [Nucleic acid ligands that bind to and inhibit DNA polymerases](#)
- 6020206- [Homocysteine assay](#)
- 6020483- [Nucleoside modifications by palladium catalyzed methods](#)
- 6028186- [High affinity nucleic acid ligands of cytokines](#)
- 6030776- [Parallel SELEX](#)
- 6048698- [Parallel SELEX.TM.](#)
- 6083696- [Systematic evolution of ligands exponential enrichment: blended selex](#)
- 6110900- [Nucleic acid ligands](#)
- 6114120- [Systematic evolution of ligands by exponential enrichment: tissue selex](#)
- 6252060- [Antiviral liponucleosides: treatment of hepatitis B](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2010 - BioPortfolio Limited.

